Qiagen N.V. (QIA.F)
- Previous Close
40.13 - Open
40.40 - Bid --
- Ask --
- Day's Range
39.87 - 40.40 - 52 Week Range
32.50 - 47.53 - Volume
168 - Avg. Volume
1,292 - Market Cap (intraday)
8.656B - Beta (5Y Monthly) 0.67
- PE Ratio (TTM)
105.18 - EPS (TTM)
0.38 - Earnings Date Jul 31, 2025 - Aug 4, 2025
- Forward Dividend & Yield 0.22 (0.55%)
- Ex-Dividend Date Jul 2, 2025
- 1y Target Est
44.03
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, such as assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables, such as short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments; bioinformatics solutions; and custom laboratory and genomic services. The company provides software-as-a-service. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
www.qiagen.com5,700
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: QIA.F
View MorePerformance Overview: QIA.F
Trailing total returns as of 6/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: QIA.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: QIA.F
View MoreValuation Measures
Market Cap
8.60B
Enterprise Value
8.99B
Trailing P/E
106.74
Forward P/E
19.01
PEG Ratio (5yr expected)
1.04
Price/Sales (ttm)
4.98
Price/Book (mrq)
2.92
Enterprise Value/Revenue
5.14
Enterprise Value/EBITDA
27.66
Financial Highlights
Profitability and Income Statement
Profit Margin
4.68%
Return on Assets (ttm)
5.75%
Return on Equity (ttm)
2.67%
Revenue (ttm)
2B
Net Income Avi to Common (ttm)
93.68M
Diluted EPS (ttm)
0.38
Balance Sheet and Cash Flow
Total Cash (mrq)
969.88M
Total Debt/Equity (mrq)
41.36%
Levered Free Cash Flow (ttm)
622.84M